Athira Pharma Inc
Change company Symbol lookup
Select an option...
ATHA Athira Pharma Inc
PATK Patrick Industries Inc
TGHI Touchpoint Group Holdings Inc
PIAI^ Prime Impact Acquisition I
CGEN Compugen Ltd
FPAY FlexShopper Inc
IOACW Innovative International Acquisition Equity Warrants Exp 26th Oct 2026 *W EXP 10/26/2026
FUSN Fusion Pharmaceuticals Inc
COUR Coursera Inc
SIMO Silicon Motion Technology Corp
Go

Health Care : Pharmaceuticals |
Company profile

Athira Pharma, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing small molecules to restore neuronal health and stop neurodegeneration. The Company's lead candidate, fosgonimeton (ATH-1017), is a subcutaneously administered, blood brain barrier (BBB)-penetrating, small molecule HGF/MET positive modulator. The primary target indication is Alzheimers disease. The ATH-1017, is a subcutaneous administered, BBB-penetrating, small molecule hepatocyte growth factor/mesenchymal-epithelial transition factor (HGF/MET) activator for the treatment of neurodegenerative disorders, with an initial focus on Alzheimer's disease (AD). It also has preclinical candidates for non-AD indications, including ATH-1018, which is being developed to address peripheral indications, and ATH-1019/ATH-1020 compounds, which are being advanced to address neuropsychiatric indications. ATH technology is designed to promote HGF/MET activity for a variety of clinical applications.

Closing Price
$3.90
Day's Change
0.15 (4.00%)
Bid
--
Ask
--
B/A Size
--
Day's High
4.00
Day's Low
3.77
Volume
(Light)
Volume:
342,544

10-day average volume:
453,880
342,544

Display:

Providers:

UpdateCancel
6 providers
August 03, 2022
Athira Pharma Presents Data from ACT-AD Phase 2 Proof-of-Concept Clinical Study of Fosgonimeton in Mild-to-Moderate Alzheimer's Patients at the Alzheimer's Association International Conference 2022

EQNX::TICKER_START (NASDAQ:ATHA), EQNX::TICKER_END Additional data showed numerical improvement in activities of daily living (ADCS-ADL23), a protocoled secondary endpoint and a functional measure of independence (Globe Newswire)

August 02, 2022
Athira Pharma Presents Preclinical Data at the Alzheimer's Association International Conference 2022

EQNX::TICKER_START (NASDAQ:ATHA), EQNX::TICKER_END Fosgo-AM, the active metabolite of Fosgonimeton (ATH-1017), demonstrates neuroprotective effects in primary neuron cultures New orally available small molecule positive modulators of HGF/MET reverse...(Globe Newswire)

July 25, 2022
Athira Pharma to Present Clinical and Preclinical Data at Alzheimer's Association International Conference 2022

EQNX::TICKER_START (NASDAQ:ATHA), EQNX::TICKER_END Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration, today announced the...(Globe Newswire)

June 22, 2022
Athira Pharma Announces Topline Results from ACT-AD Phase 2 Proof of Concept Study of Fosgonimeton in Mild-to-Moderate Alzheimer's Disease

EQNX::TICKER_START (NASDAQ:ATHA), EQNX::TICKER_END Primary endpoint of change in biomarker ERP P300 latency was not statistically significant for the full study population as combination of fosgonimeton and standard-of-care (AChEIs) given together...(Globe Newswire)

June 07, 2022
Athira Pharma Announces Formation of Scientific Advisory Board Comprised of Renowned Leaders in Neurology Research

EQNX::TICKER_START (NASDAQ:ATHA), EQNX::TICKER_END Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration, today announced the...(Globe Newswire)

May 27, 2022
ATHIRA PHARMA INVESTIGATION CONTINUED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Continues to Investigate the Officers and Directors of Athira Pharma, Inc. - ATHA

Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC ("KSF"), announces that KSF continues its investigation into Athira Pharma, Inc. (NasdaqGS: ATHA). (BusinessWire)

May 20, 2022
ATHIRA ALERT: Bragar Eagel & Squire, P.C. Is Investigating Athira Pharma, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm

Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Athira Pharma, Inc. (NASDAQ: ATHA) on behalf of long-term stockholders following a class action complaint that was filed...(BusinessWire)

May 19, 2022
Shareholders Approve the Election of All Three Athira Director Nominees at 2022 Annual Meeting

EQNX::TICKER_START (NASDAQ:ATHA), EQNX::TICKER_END Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration, today announced...(Globe Newswire)

Earnings Calendar and Events Data provided by |Terms of Use| © 2022 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

"Hot" indicates urgent and noteworthy news stories as determined by providers Dow Jones or Benzinga. TD Ameritrade does not select or recommend "hot" stories.

Information and news provided by ,, , Computrade Systems, Inc., ,, and

Copyright © 2022. All rights reserved.